Table 1

Failures of 13-Valent Conjugated Pneumococcal Vaccine in Age-Appropriately Vaccinated Children 2–59 Months of Age, Spain

Sergi Hernández

, Fernando Moraga-Llop, Alvaro Díaz, Mariona F. de Sevilla, Pilar Ciruela, Carmen Muñoz-Almagro, Gemma Codina, Magda Campins, Juan José García-García, Cristina Esteva, Conchita Izquierdo, Sebastià González-Peris, Johanna Martínez-Osorio, Sonia Uriona, Luis Salleras, and Ángela Domínguez

Author affiliations: Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Barcelona, Spain (S. Hernández, P. Ciruela, C. Izquierdo); Hospital Universitari Vall d’Hebron, Barcelona (F. Moraga-Llop, M. Campins, S. González-Peris); Hospital de Nens, Barcelona (A. Díaz); Hospital Sant Joan de Déu Barcelona, Barcelona (M.F. de Sevilla, C. Muñoz-Almagro, J.J. García-García, C. Esteva, J. Martínez-Osorio); Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain (M.F. de Sevilla, C. Muñoz-Almagro, J.J. García-García); CIBER de Epidemiología y Salud Pública, Madrid, Spain (P. Ciruela, J.J. García-García, C. Esteva, L. Salleras, Á. Domínguez); Universitat Internacional de Catalunya, Barcelona (C. Muñoz-Almagro); Vall d’Hebron Institut de Recerca, Barcelona (M. Campins, S. Uriona); Universitat de Barcelona, Barcelona (L. Salleras, Á. Domínguez)

Main Article

Characteristics of age-appropriately vaccinated patients 2–59 months of age with invasive pneumococcal disease caused by PCV13 serotypes, Catalonia, Spain, 2012–2016*

Pt no.	Age, mo/sex	Year	Age at vaccination	Schedule	Clinical manifestation	Complications	Outcome	DT	Ser	Vaccine schedule
1	19/F	2012	12 mo	1	Complicated pneumonia	Pleural effusion	Cured	PCR	19A	UC
2	15/M	2012	3 ,5 mo†	2 + 0	Complicated pneumonia	Empyema, pneumothorax	Cured	Culture, PCR	19A	UC
3	15/F	2012	2, 5, 8 mo	3 + 0	Complicated pneumonia	Empyema, necrotizing pneumonia, bronchoalveolar fistula, pneumothorax	Bronchopleural fistula	PCR	3	UC
4	23/M	2012	17 mo	1	Uncomplicated pneumonia		Cured	Culture	1	UC
5	24/M	2012	2, 4, 6, 18 mo	3 + 1	Complicated pneumonia	Empyema	Cured	PCR	19A	C
6	24/M	2012	12, 21 mo	2	Complicated pneumonia	Empyema	Cured	PCR	3	C
7	21/M	2012	3, 5, 7, 15 mo	3 + 1	Complicated pneumonia	Empyema	Cured	PCR	3	C
8	38/M	2012	30 mo	1	Bacteraemic mastoiditis	Epidural abscess, sigmoid sinus thrombosis	Hydrocephalus	PCR	3	C
9	9/F	2013	2, 3, 4 mo	3 + 0	Complicated pneumonia	Necrotizing pneumonia	Cured	PCR	19A	UC
10	12/M	2013	2, 4, 6 mo	3 + 0	Complicated pneumonia	Empyema, necrotizing pneumonia	Cured	PCR	6B	UC
11	50/F	2013	25 mo	1	Complicated pneumonia	Empyema	Cured	PCR	3	C
12	34/M	2013	3, 6, 9, 15 mo	3 + 1	Complicated pneumonia	Empyema, pneumothorax, bronchopleural fistula	Cured	Culture, PCR	3	C
13	15/M	2014	2, 4, 7 mo	3 + 0	Osteoarticular infection		Cured	Culture	19A	UC
14	43/M	2014	12, 15 mo	2	Complicated pneumonia	Empyema, necrotizing pneumonia, bronchopleural fistula	Cured	PCR	3	C
15	44/F	2014	3, 5, 7, 20 mo	3 + 1	Complicated pneumonia	Empyema	Cured	PCR	3	C
16	25/F	2015	2, 4, 6, 14 mo	3 + 1	Complicated pneumonia	Pleural effusion	Cured	Culture	14	C
17	29/M	2015	3, 5, 7, 18 mo	3 + 1	Complicated pneumonia	Necrotizing pneumonia	Cured	PCR	3	C
18	51/M	2015	2, 4, 6, 16 mo	3 + 1	Complicated pneumonia	Empyema	Cured	PCR	3	C
19	49/F	2015	12,14 mo	2	Complicated pneumonia	Empyema	Cured	PCR	3	C
20	54/F	2015	3, 5, 7,17 mo	3 + 1	Complicated pneumonia	Empyema	Cured	PCR	3	C
21	58/M	2016	14, 16 mo	2	Complicated pneumonia	Empyema, necrotizing pneumonia	Pneumatocele	PCR	3	C
22	35/M	2016	2, 5, 9, 18 mo	3 + 1	Complicated pneumonia	Empyema, necrotizing pneumonia	Cured	PCR	3	C
23	41/M	2016	3, 4, 7, 16 mo	3 + 1	Complicated pneumonia	Necrotizing pneumonia	Cured	PCR	3	C
24	23/M	2016	3, 5, 6, 15 mo	3 + 1	Complicated pneumonia	Pleural effusion	Cured	PCR	3	C

*C, completed; DT, diagnostic technique; Pt, patient; Ser, serotype; UC, uncompleted.
†Patient resident in Andorra (routine immunization schedule 2+1) and transferred to a participating hospital.

Main Article

Page created: May 18, 2020

Page updated: May 18, 2020

Page reviewed: May 18, 2020

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

Volume 26, Number 6—June 2020

Research

Failures of 13-Valent Conjugated Pneumococcal Vaccine in Age-Appropriately Vaccinated Children 2–59 Months of Age, Spain

Table 1